Ingredients

Ingredient sets that include narasin

Ordered by report count. FDA states that these data "cannot be used to estimate the risk associated with the product or compare one drug or device product with another"; counts follow sales volume and years on the market. A report can list more than one set, so shares can add to more than 100%.

Signs listed in reports, pooled

share of narasin reports listing the termall reports in the database

1. Death44%314
2. Lack of efficacy (protozoa) - Coccidia[the product did not have the expected effect: coccidia]22.8%163
3. Increased mortality rate9.8%70
4. Lameness8.3%59
5. Granules/Powder, Abnormal8.1%58
6. Accidental exposure[exposure that was not intended]8%57
7. Death by euthanasia[the animal was euthanized]7.4%53
8. Recumbency[lying down and unable or unwilling to rise]6.3%45
9. Lack of efficacy - NOS[the product did not have the expected effect]5.3%38
10. NT - Abnormal necropsy finding NOS[NOS: not otherwise specified]4.8%34
11. Loss of egg quantity4.6%33
12. Enteritis4.5%32
13. Anorexia[not eating]3.9%28
14. Digestive tract disorder NOS[digestive problem, type not specified]3.6%26
15. Respiratory tract disorder NOS[NOS: not otherwise specified]3.6%26
16. Vocalisation[crying out or unusual noise]3.5%25
17. Unclassifiable adverse event[event that fits no dictionary term]2.9%21
18. Inappropriate preparation of medication2.7%19
19. Necropsy performed2.5%18
20. Rectal prolapse2.2%16
21. Residues in eggs2.2%16
22. Dehydration2.1%15
23. Systemic disorder NOS[NOS: not otherwise specified]2.1%15
24. Diarrhoea[diarrhea]2%14
25. Musculoskeletal disorder NOS[NOS: not otherwise specified]2%14
26. Unthrifty2%14
27. Lethargy[unusually tired or inactive]1.8%13
28. Pneumonia[lung infection or inflammation]1.8%13
29. Abnormal necropsy finding1.7%12
30. Ataxia[unsteady, uncoordinated movement]1.7%12

Pooled across every ingredient set and every report that names the ingredient. One report can list several terms and several drugs; a term here may relate to any of them or to none.

Monthly reports by species, five years

By month of receipt; each panel has its own scale. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Outcomes, report types and ages

Coloured bar: reports naming narasin. Grey bar: all 1,357,245 reports. Outcomes are as stated by the reporter; FDA has not necessarily determined whether any product played a part.

In context

Shares of reports, not of animals treated: how many animals receive the ingredient is not public. Ingredients used in anaesthesia, cancer care or in old animals carry more serious outcomes in their reports for that reason alone.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Ingredient names follow the Green Book; salts and forms are kept as FDA lists them. Drug entries are matched by the active ingredients their unmasked ingredient field discloses. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.